Bio-Path Holdings, Inc. (BPTH)

NASDAQ: BPTH · IEX Real-Time Price · USD
0.539
-0.030 (-5.25%)
At close: Dec 7, 2023, 3:59 PM
0.535
-0.004 (-0.76%)
After-hours: Dec 7, 2023, 7:14 PM EST
-5.25%
Market Cap 6.71M
Revenue (ttm) n/a
Net Income (ttm) -16.67M
Shares Out 12.35M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 129,448
Open 0.529
Previous Close 0.569
Day's Range 0.505 - 0.543
52-Week Range 0.320 - 2.350
Beta 0.97
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2023

About BPTH

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also d... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 10
Stock Exchange NASDAQ
Ticker Symbol BPTH
Full Company Profile

Financial Performance

Financial Statements

News

Bio-Path Holdings Reports Third Quarter 2023 Financial Results

HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop ...

22 days ago - GlobeNewsWire

Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023

HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a por...

4 weeks ago - GlobeNewsWire

Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET

6 weeks ago - GlobeNewsWire

Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference

HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...

3 months ago - GlobeNewsWire

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23

Dallas, Texas--(Newsfile Corp. - August 30, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2023. The full ...

3 months ago - Newsfile Corp

Bio-Path Holdings Reports Second Quarter 2023 Financial Results

HOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop ...

4 months ago - GlobeNewsWire

Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023

HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) --  Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...

4 months ago - GlobeNewsWire

Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering

HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanopartic...

4 months ago - GlobeNewsWire

Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

Interim Data Analysis Demonstrates Significant Clinical Improvement and Tolerable Safety Profile in High-Risk Patients

4 months ago - GlobeNewsWire

Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Advancing to Second Cohort of Phase 1/1b Clinical Trial Evaluating BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Advancing to Second Cohort...

5 months ago - GlobeNewsWire

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23

Dallas, Texas--(Newsfile Corp. - June 2, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can be a...

6 months ago - Newsfile Corp

Bio-Path Holdings Reports First Quarter 2023 Financial Results

HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a...

7 months ago - GlobeNewsWire

Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023

HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

7 months ago - GlobeNewsWire

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 '22

Dallas, Texas--(Newsfile Corp. - April 10, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q422...

8 months ago - Newsfile Corp

Bio-Path Holdings Reports Full Year 2022 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

8 months ago - GlobeNewsWire

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...

9 months ago - GlobeNewsWire

Bio-Path Holdings Provides Clinical and Operational Update

Company Expects to Achieve Several Near-Term Clinical Milestones Company Expects to Achieve Several Near-Term Clinical Milestones

9 months ago - GlobeNewsWire

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 '22

Dallas, Texas--(Newsfile Corp. - December 19, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can...

1 year ago - Newsfile Corp

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Phase 1/1b Clinical Trial Evaluating Ability ...

1 year ago - GlobeNewsWire

Bio-Path Holdings Reports Third Quarter 2022 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

1 year ago - GlobeNewsWire

Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022

HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a por...

1 year ago - GlobeNewsWire

Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement

HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop ...

1 year ago - GlobeNewsWire

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cell's Ability to Produce Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients...

1 year ago - GlobeNewsWire

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH)

Dallas, Texas--(Newsfile Corp. - September 30, 2022) - Bio-Path Holdings, Inc. (Nasdaq: BPTH): The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_...

1 year ago - Newsfile Corp

Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference

HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...

1 year ago - GlobeNewsWire